Prime Medicine (PRME) EBITDA (2021 - 2026)

Prime Medicine's EBITDA history runs 6 years deep, the most recent figure standing at -$50.7 million for Q1 2026.

• Quarterly EBITDA rose 3.32% year-over-year to -$50.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$206.6 million (changed 0.05% YoY) and the FY2025 annual result came in at -$208.4 million, down 2.91% from the prior year.
• EBITDA was -$50.7 million for Q1 2026 at Prime Medicine, down from -$48.6 million in the prior quarter.
• Across five years, EBITDA topped out at -$19.9 million in Q1 2022 and bottomed at -$68.0 million in Q4 2023.
• A 5-year average of -$46.0 million and a median of -$48.6 million in 2025 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 35.6% in 2022, while the deepest fall reached 203.59% in 2022.
• Prime Medicine's EBITDA stood at -$38.7 million in 2022, then slumped by 75.89% to -$68.0 million in 2023, then surged by 35.01% to -$44.2 million in 2024, then dropped by 9.92% to -$48.6 million in 2025, then fell by 4.21% to -$50.7 million in 2026.
• Business Quant data shows PRME's EBITDA at -$50.7 million in Q1 2026, -$48.6 million in Q4 2025, and -$54.0 million in Q3 2025.